Celgene Moves Into Solid Tumors With $2.9 Billion Abraxis Acquisition

Celgene is acquiring Abraxane developer Abraxis Biosciences and planning an aggressive development and marketing push for the novel nanoparticle formulation of paclitaxel, with the aim of driving the drug's sales to $1 billion by 2015